{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:43:35Z","timestamp":1788533015027,"version":"build-2803163510"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Fibroblast growth factor (FGF)-23 levels rise as kidney function declines. Whether elevated FGF-23 levels are associated with an increased risk for contrast-associated acute kidney injury (CA-AKI) and major adverse cardiovascular events (MACE) in patients undergoing coronary angiography remain uncertain.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>In total, 492 patients receiving coronary angiography were enrolled. Their serum FGF-23 levels were measured before administration of contrast media. The occurrence of CA-AKI was defined as a rise in serum creatinine of 0.5 mg\/dL or a 25% increase from the baseline value within 48 h after the procedure. All patients were followed up for at least 1 year or until the occurrence of MACE including death, nonfatal myocardial infarction (MI), and ischemic stroke.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, CA-AKI occurred in 41 (8.3%) patients. During a median follow-up of 2.6 years, there were 24 deaths, 3 nonfatal MIs, and 7 ischemic strokes. Compared with those in the lowest FGF-23 tertile, individuals in the highest FGF-23 tertile had a significantly higher incidence of CA-AKI (P &lt; 0.001) and lower incidence of MACE-free survival (P = 0.001). In multivariate regression analysis, higher FGF-23 level was found to be independently associated with a graded risk for CA-AKI (OR per doubling, 1.90; 95% CI 1.48\u20132.44) and MACE (HR per doubling, 1.25; 95% CI 1.02\u20131.52).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Elevated FGF-23 levels were associated with an increased risk for CA-AKI and future MACE among patients undergoing coronary angiography. FGF-23 may play a role in early diagnosis of CA-AKI and predicting clinical outcomes after coronary angiography.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0254835","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T17:28:11Z","timestamp":1627061291000},"page":"e0254835","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Significance of serum FGF-23 for risk assessment of contrast-associated acute kidney injury and clinical outcomes in patients undergoing coronary angiography"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0338-1702","authenticated-orcid":true,"given":"Shao-Sung","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hsun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Bang","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7178-2316","authenticated-orcid":true,"given":"Jaw-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing-Jong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"pone.0254835.ref001","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ccc.2004.12.003","article-title":"Contrast-induced nephropathy","volume":"21","author":"PA McCullough","year":"2005","journal-title":"Crit Care Clin"},{"key":"pone.0254835.ref002","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2214\/ajr.183.6.01831673","article-title":"Contrast-induced nephropathy","volume":"183","author":"TG Gleeson","year":"2004","journal-title":"Am J Roentgenol"},{"key":"pone.0254835.ref003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjcard.2004.08.056","article-title":"Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables","volume":"95","author":"G Dangas","year":"2005","journal-title":"Am J Cardiol"},{"key":"pone.0254835.ref004","first-page":"1393","article-title":"A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation","volume":"44","author":"R Mehran","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"pone.0254835.ref005","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s00330-011-2225-0","article-title":"Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast-induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines","volume":"21","author":"F Stacul","year":"2011","journal-title":"Eur Radiol"},{"key":"pone.0254835.ref006","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ki.5000368","article-title":"Contrast-induced nephropathy: definition, epidemiology, and patients at risk","author":"R Mehran","year":"2006","journal-title":"Kidney Int Suppl"},{"key":"pone.0254835.ref007","doi-asserted-by":"crossref","first-page":"14K","DOI":"10.1016\/j.amjcard.2006.01.020","article-title":"CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy","volume":"98","author":"J Tumlin","year":"2006","journal-title":"Am J Cardiol"},{"key":"pone.0254835.ref008","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9343(97)00150-2","article-title":"Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality","volume":"103","author":"PA McCullough","year":"1997","journal-title":"Am J Med"},{"key":"pone.0254835.ref009","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0735-1097(02)01745-X","article-title":"The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous interventions","volume":"39","author":"PJ Best","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"pone.0254835.ref010","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/01.CIR.0000016043.87291.33","article-title":"Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention","volume":"105","author":"CS Rihal","year":"2002","journal-title":"Circulation"},{"key":"pone.0254835.ref011","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"T Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"pone.0254835.ref012","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"M Wolf","year":"2012","journal-title":"Kidney Int"},{"key":"pone.0254835.ref013","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: the Cardiovascular Health Study","volume":"60","author":"JH Ix","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"pone.0254835.ref014","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"T Isakova","year":"2011","journal-title":"JAMA"},{"key":"pone.0254835.ref015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"OM Gutie\u00b4rrez","year":"2008","journal-title":"N Engl J Med"},{"key":"pone.0254835.ref016","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2215\/CJN.00550112","article-title":"FGF-23 levels in patients with AKI and risk of adverse outcomes","volume":"7","author":"DE Leaf","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0254835.ref017","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.13281211","article-title":"Chronic Renal Insufficiency Cohort. Fibroblast growth factor 23 and Inflammation in CKD","volume":"7","author":"JM Mendoza","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0254835.ref018","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000356118","article-title":"The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers","volume":"3","author":"MM Nasrallah","year":"2013","journal-title":"Nephron Extra"},{"key":"pone.0254835.ref019","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1681\/ASN.2006040368","article-title":"Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease","volume":"17","author":"YC Ma","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"pone.0254835.ref020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00398.x","article-title":"Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease","volume":"68","author":"M Tonelli","year":"2005","journal-title":"Kidney Int"},{"key":"pone.0254835.ref021","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/j.1600-0455.2003.00119.x","article-title":"Inflammatory markers increase following exposure to radiographic contrast media","volume":"44","author":"WK Laskey","year":"2003","journal-title":"Acta Radiol"},{"key":"pone.0254835.ref022","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jacc.2007.12.035","article-title":"Contrast-induced acute kidney injury","volume":"51","author":"PA McCullough","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"pone.0254835.ref023","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1161\/CIRCULATIONAHA.112.103317","article-title":"Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury","volume":"126","author":"C Quintavalle","year":"2012","journal-title":"Circulation"},{"key":"pone.0254835.ref024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000329534","article-title":"C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention","volume":"34","author":"F Gao","year":"2011","journal-title":"Am J Nephrol"},{"key":"pone.0254835.ref025","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/0003319713482177","article-title":"Impact of preprocedural high-sensitivity C-reactive protein on contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention","volume":"65","author":"Z Jian-Wei","year":"2014","journal-title":"Angiology"},{"key":"pone.0254835.ref026","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semnephrol.2018.10.005","article-title":"Fibroblast growth factor 23 and klotho in AKI","volume":"39","author":"M Christov","year":"2019","journal-title":"Semin Nephrol"},{"key":"pone.0254835.ref027","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2215\/CJN.05830513","article-title":"Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals","volume":"9","author":"JR Brown","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0254835.ref028","doi-asserted-by":"crossref","first-page":"e0016","DOI":"10.1097\/CCE.0000000000000016","article-title":"Urine Klotho Is Lower in Critically Ill Patients With Versus Without Acute Kidney Injury and Associates With Major Adverse Kidney Events","volume":"1","author":"JA Neyra","year":"2019","journal-title":"Crit Care Explor"},{"key":"pone.0254835.ref029","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/0886022X.2018.1487860","article-title":"Serum NGAL and FGF23 may have certain value in early diagnosis of CIN","volume":"40","author":"Huihui Li","year":"2018","journal-title":"Ren Fail"},{"key":"pone.0254835.ref030","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"HOST Investigators. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"J Kendrick","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"pone.0254835.ref031","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"JJ Scialla","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"pone.0254835.ref032","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2015.12.035","article-title":"Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery","volume":"89","author":"DE Leaf","year":"2016","journal-title":"Kidney Int"},{"key":"pone.0254835.ref033","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1681\/ASN.2016080836","article-title":"Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness","volume":"28","author":"DE Leaf","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"pone.0254835.ref034","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.10810917","article-title":"Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients","volume":"13","author":"DE Leaf","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0254835.ref035","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1002\/ehf2.13020","article-title":"Fibroblast-growth-factor-23 in heart failure with preserved ejection fraction: relation to exercise capacity and outcomes","volume":"7","author":"P Kanagala","journal-title":"ESC Heart Fail. 2020"},{"key":"pone.0254835.ref036","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","article-title":"The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study","volume":"152","author":"BD Parker","year":"2010","journal-title":"Ann Intern Med"},{"issue":"6","key":"pone.0254835.ref037","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/jamacardio.2018.0653","article-title":"Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial","volume":"3","author":"BA Bergmark","year":"2018","journal-title":"JAMA Cardiol"},{"key":"pone.0254835.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2017.03.042","article-title":"Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies","volume":"261","author":"Z Qin","year":"2017","journal-title":"Atherosclerosis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0254835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T17:28:39Z","timestamp":1627061319000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0254835"}},"subtitle":[],"editor":[{"given":"Emmanuel A.","family":"Burdmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0254835","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]}}}